1 / 24

Hepatitis-2015 Orlando, USA July 20 - 22 2015

This study compares the safety and efficacy of Sofosbuvir brand (Sofaldi) and generic (MPI-Viropack) in treating chronic HCV infection in Egypt. Results show both forms to be safe and effective in Egyptian patients with comparable profiles.

hansonl
Download Presentation

Hepatitis-2015 Orlando, USA July 20 - 22 2015

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis-2015Orlando, USAJuly 20 - 22 2015 Hosny Salama

  2. Effect of Sofosbuvir , Brand drug ( Sofaldi ) versus generic ( MPIviropack ) in treating chronic HCV infection in Egypt .Prof. Hosny Salama Cairo University, Egypt.

  3. Chronic HCV infection is high in Egypt with prevalence of 12-14% . More that 85% of HCV is Genotype IV . Response of therapy to SOC therapy was around 50% with a lot of side effects and long duration of therapy

  4. With the introduction of DAAs , a new era of HCV treatment started . Sofosbuvir is a NS5B polymerase inhibitor . It has a pan-genotypic coverage and approved for use in genotype IV AASLD 2014, EASL 2015 . With the availability of both the brand drug ( Sofaldi- Gilead ) and the generic form ( MPI-Viropack- Marcyrl Pharmaceutical Industries ) in the Egypt in 2014- 2015

  5. we conducted this comparative study to evaluate and compare the safety and efficacy of both the Brand and Generic forms.

  6. In this study we recruited 105 naïve patients • with chronic HCV infection. • For all of them the following was done : • Liver function tests ( S. bilirubin, ALT, AST . Albumin , PT and PC ), • CBS , ECG, fundus examination • Abdominal ultrasound, Fibroscan • and HCV RNA Quantitative by PCR . • Patients were divided into three groups • ( 35 patients each )

  7. According to Fibroscan : Group I : F2 ( 23 pts ) , F3 (9 pts) and F4 ( 3 pts ). Group II : F2 ( 22 pts ) , F3 (10 pts ) and F4 ( 3 pts ) Group III : F2 ( 22 pts ), F3 ( 6 pts ) and F4 ( 7 pts ) .

  8. For the first group, triple therapy was used, Peg Interferon ( Peg Intron- MSD according to body weight) , Ribavirin in a weight adjusted dosage and Sofaldi- Gilead 400 mg once daily . For the second group, triple therapy was also used, Peg Interferon and Ribavirin as in group I and MPIviropack 400 mg once daily . For the third group, dual therapy was given using Ribavirin in a weight adjusted dosage and either Sofaldi 400 mg once daily (17 patients ) or MPIviropack once daily ( 18 patients )

  9. Follow – up after one and three months using liver function tests, CBC and HCV RNA by PCR was done .

  10. There was normalization of liver enzymes in 34 ( 97%) patients group I and II, and 35 (100%) patients in the third group. CBC showed mild decrease in HB level in 18 (51%) , 19 (54%), 15 (43%) patients in group I, II , III respectively

  11. HCV RNA was un-detected in 34 (97%) patients in group I , II and III after One and 3 months during therapy .

  12. The side effects were comparable in group I , II and III : • * Nausea and abdominal Pain in 20 (57%) patients in Gr. I versus 21 ( 60%) in Gr. II, III . • Diarrhea in 3 (8.5%) patients in Gr. I versus 4 ( 11.4%) patients in Gr. II , III . • * Athenia and exhaustion in 23 ( 66%) in all groups • * Headache in 4 (11.4%) patients in all groups . • However in Group III the side effects were mild including asthenia in 23 (66%) patients and mild gastric upset in 15 (43%) patients .

  13. Follow-up is still going on to assess the SVR 12, 24 after the end of treatment : Treatment for 3 months in Group I, II and 6 months in group III .

  14. From this pilot study, we found that both the brand and the generic forms of Sofosbuvir in combination with Peg/R or with Ribavirin alone : Proved to be safe and effective in Egyptian patients with naïve chronic HCV – genotype 4 infection with comparable safety and efficacy profile . The long term follow-up to assess the SVR in 12, 24 weeks are still going on .

  15. Acknolgement Abdel Rahman Zekri2, EmanMedhat1 , Mervat Al Ansary,3 and Sherine A. Alim1 (Hepatology1 , Clinical Pathology2 and Virology Unit at NCI 3, Cairo University, Cairo, Egypt )

  16. THANK YOU

  17. Meet the eminent gathering once again atHepatitis-2016Dubai, UAEOctober 17 - 19, 2016 Hepatitis– 2016 Website: hepatitis.omicsgroup.com

More Related